2 completed. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
Follow Leukemia, Chronic Myelogenous: new trials by email Literature Review of Leukemia, Chronic Myelogenous trials Research Report on Leukemia, Chronic Myelogenous
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors asciminib, best available treatment - Leukemia, Chronic Myelogenous | Phase 2 | Completed | Novartis Pharmaceuticals | 84 | 2021-12-06 | 2025-04-18 |
| Study of Bosutinib in Japanese Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia Bosutinib - Leukemia, Chronic Myelogenous | Phase 2 | Completed | Pfizer | 64 | 2017-05-15 | 2022-05-19 |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Bronchiolitis Obliterans Syndrome (1)
Bone Marrow Diseases (2) · Chronic Disease (2) · Disease Attributes (2) · Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Leukemia (2) · Leukemia, Myeloid (2) · Myeloproliferative Disorders (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Bronchial Diseases (1) · Bronchiolitis (1) · Bronchiolitis Obliterans (1)
Novartis Pharmaceuticals (1) · Pfizer (1)
China (1) · Japan (1)